Can you discuss the immunogencity issues --i.e., anti-drug antibodies (ADAs) -- for biosimilars vs reference biologics?

Can you discuss the immunogencity issues --i.e., anti-drug antibodies (ADAs) -- for biosimilars vs reference biologics?

Can you discuss the immunogencity issues —i.e., anti-drug antibodies (ADAs) — for biosimilars vs reference biologics; and how we can apply results of clinical trials comparing biosimilar anti-TNFs to the front lines of drug selection and RA patient care?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Joseph Markenson, MD

Joseph Markenson, MD

Department of Rheumatology
Department of Medicine
Hospital for Special Surgery, New York, NY
Attending Physician, Hospital for Special Surgery
Professor of Clinical Medicine, Weill Cornell Medical College